Clotrimazole-Betamethasone Dipropionate Prescribing for Nonfungal Skin Conditions

Jeremy A W Gold; Avrom S Caplan; Kaitlin Benedict; Shari R Lipner; Dallas J Smith

doi:10.1001/jamanetworkopen.2024.11721

Clotrimazole-Betamethasone Dipropionate Prescribing for Nonfungal Skin Conditions

JAMA Netw Open. 2024 May 1;7(5):e2411721. doi: 10.1001/jamanetworkopen.2024.11721.

Authors

Jeremy A W Gold¹, Avrom S Caplan², Kaitlin Benedict¹, Shari R Lipner³, Dallas J Smith¹

Affiliations

¹ Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
² Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York.
³ Department of Dermatology, Weill Cornell Medicine, New York, New York.

No abstract available

Plain language summary

This cross-sectional study identifies the common diagnoses and physician encounter types associated with clotrimazole-betamethasone dipropionate prescriptions among Medicare enrollees in 2021.

MeSH terms

Adult
Antifungal Agents / therapeutic use
Betamethasone* / analogs & derivatives
Betamethasone* / therapeutic use
Clotrimazole* / therapeutic use
Drug Combinations
Female
Humans
Male
Middle Aged
Practice Patterns, Physicians' / statistics & numerical data
Skin Diseases / drug therapy

Substances

betamethasone-17,21-dipropionate